Goldman Sachs Group Inc Vaxart, Inc. Transaction History
Goldman Sachs Group Inc
- $706 Billion
- Q2 2025
A detailed history of Goldman Sachs Group Inc transactions in Vaxart, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 97,407 shares of VXRT stock, worth $34,092. This represents 0.0% of its overall portfolio holdings.
Number of Shares
97,407
Previous 76,156
27.9%
Holding current value
$34,092
Previous $31,000
38.71%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding VXRT
# of Institutions
102Shares Held
23.1MCall Options Held
66.1KPut Options Held
0-
Vanguard Group Inc Valley Forge, PA10.4MShares$3.65 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.33MShares$814,2290.0% of portfolio
-
Black Rock Inc. New York, NY1.77MShares$621,0210.0% of portfolio
-
Marshall Wace, LLP London, X01.76MShares$617,3580.0% of portfolio
-
State Street Corp Boston, MA851KShares$297,8910.0% of portfolio
About Vaxart, Inc.
- Ticker VXRT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 126,506,000
- Market Cap $44.3M
- Description
- Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...